alanine + arginine + aspartic acid + 20 other active ingredients: prescribing and clinical use
Focused clinical detail for use alongside current product information, local policy and patient-specific assessment.
alanine + arginine + aspartic acid + 20 other active ingredients: clinical details
Prescribing considerations
- Assess individual amino-acid, energy, electrolyte and fluid requirements and account for other intravenous glucose or electrolyte sources.
- Correct fluid, electrolyte and acid–base disturbances before infusion.
- Correct pre-existing thiamine deficiency before giving the glucose-containing solution.
- Consider additional lipid, essential fatty acids, vitamins and trace elements.
- Use strict aseptic technique and confirm compatibility before adding any component.
- Use caution in cardiac, renal, hepatic, adrenal or pulmonary impairment and in increased serum osmolarity.
Contraindications and cautions
- Hypersensitivity to an active ingredient or excipient
- Inborn errors of amino-acid metabolism
- Uncontrolled hyperglycaemia
- Acidosis
- Intracranial or intraspinal haemorrhage
- Severe hepatic insufficiency
- Severe renal insufficiency without renal replacement therapy
- Newborn infants, infants and children younger than 2 years
- Life-threatening circulatory instability, fluid overload or pulmonary oedema
- Acute myocardial infarction, stroke or an unstable metabolic state
Monitoring
- Blood glucose
- Serum electrolytes, especially potassium, phosphate and magnesium during refeeding
- Fluid balance, weight and urine output
- Acid–base balance and serum osmolarity where relevant
- Renal and hepatic function
- Temperature and central-line site
- Blood count and coagulation during prolonged administration
Clinical pharmacology
Intravenous administration makes amino acids, glucose and electrolytes immediately available. Amino acids support protein and nitrogen-containing molecule synthesis; glucose is metabolised for energy and may contribute to lipid synthesis; excess glucose may be excreted once the renal threshold is exceeded.
Formulation and product differences
- Two-chamber bag separating the amino-acid/electrolyte solution from the glucose/calcium solution until activation.
- Hyperosmolar formulation intended only for central venous infusion.
- Does not itself provide lipid, essential fatty acids, vitamins or trace elements.
- Only clear solution from an intact bag should be used; compatible additions require aseptic preparation and filtration.
alanine + arginine + aspartic acid + 20 other active ingredients interactions
The clinical team should review all medicines and other intravenous products because the infusion contains glucose, potassium, sodium, calcium, magnesium and phosphate.
Corticosteroids or adrenocorticotropic hormone
These can promote sodium and fluid retention, increasing the need to monitor fluid status.
Potassium-sparing diuretics
Medicines such as spironolactone, triamterene or amiloride may increase the risk of high blood potassium.
ACE inhibitors
Medicines such as captopril or enalapril may increase blood potassium when combined with potassium-containing solutions.
Sources
These sources were used to prepare and review this medicine page.
Prepared and reviewed by the iatroX editorial team.